<p>阿里高斯治疗公司（NASDAQ:ALGS - 获取免费报告）的股票在周五发布给客户和投资者的研究报告中被 Weiss Ratings 的股票研究人员重申了 “卖出（d-）” 评级，Weiss Ratings 报告称。</p>
<p>另外，HC Wainwright 在 9 月 12 日的研究报告中重新发布了 “买入” 评级，并设定了阿里高斯治疗公司股票的目标价为 50.00 美元。一位投资分析师对该股票给予了买入评级，另一位则给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “持有”，平均目标价为 50.00 美元。</p>
<p>获取 <strong>阿里高斯治疗公司</strong> 的提醒：</p>
<p><strong>查看我们关于 ALGS 的最新报告</strong></p>
<h2>阿里高斯治疗公司股票表现</h2>
<p>周五，ALGS 上涨 0.20 美元，达到 9.69 美元。该公司交易了 26,275 股，较其平均交易量 150,831 股有所减少。阿里高斯治疗公司的 12 个月低点为 3.76 美元，12 个月高点为 46.80 美元。该公司的市值为 5959 万美元，市盈率为-0.49，贝塔值为 2.77。该股票的 50 日移动平均线为 10.07 美元，200 日移动平均线为 7.87 美元。</p>
<p>阿里高斯治疗公司（NASDAQ:ALGS - 获取免费报告）最近于 8 月 6 日宣布了其季度财报。该公司报告的每股收益为（1.53 美元），超出分析师的共识预期（2.35 美元）0.82 美元。该公司本季度的收入为 97 万美元，而共识预期为 43 万美元。阿里高斯治疗公司的股本回报率为-22.41%，净利润率为-2337.24%。作为一个整体，股票研究分析师预计阿里高斯治疗公司在当前财政年度将发布-10.36 的每股收益。</p>
<h2>对阿里高斯治疗公司的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近对 ALGS 的持仓进行了调整。Golden State Wealth Management LLC 在第一季度将其在阿里高斯治疗公司的持仓增加了 100.0%。Golden State Wealth Management LLC 现在拥有该公司 5,348 股股票，价值 44,000 美元，此前在上个季度又购买了 2,674 股。Adage Capital Partners GP L.L.C.在第一季度将其在阿里高斯治疗公司的持仓增加了 43.1%。Adage Capital Partners GP L.L.C.现在拥有该公司 465,000 股股票，价值 3,836,000 美元，此前在上个季度又购买了 140,000 股。Heights Capital Management Inc.在第一季度收购了阿里高斯治疗公司的新股份，价值约 1,992,000 美元。Readystate Asset Management LP 在第一季度收购了阿里高斯治疗公司的新股份，价值约 375,000 美元。最后，Alyeska Investment Group L.P.在第一季度收购了阿里高斯治疗公司的新股份，价值约 3,399,000 美元。机构投资者和对冲基金持有该公司 60.43% 的股票。</p>
<h2>阿里高斯治疗公司简介</h2>
<p>（获取免费报告）</p>
<p>阿里高斯治疗公司是一家临床阶段的生物制药公司，专注于开发新型治疗药物，以满足病毒和肝病领域未满足的医疗需求。其药物候选者 ALG-055009 是一种小分子 THR-ß激动剂，目前正在进行非酒精性脂肪性肝炎（NASH）的 2a 期临床试验。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过阿里高斯治疗公司</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>罗技在财报前瞄准突破——花旗看到 30% 的上涨空间</li>
<li>股票中的死亡交叉是什么？</li>
<li>3 只区域银行股票在第三季度财报中表现出色</li>
<li>ETF 支付股息吗？你需要知道的事项</li>
<li>Freeport-McMoRan 尽管印尼停产仍发布强劲财报</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在阿里高斯治疗公司吗？</h2>
<p>在你考虑阿里高斯治疗公司之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而阿里高斯治疗公司并不在名单上。</p>
<p>虽然阿里高斯治疗公司目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ALGS

<p>Weiss Ratings 重申了对 Aligos Therapeutics (NASDAQ:ALGS) 的 “卖出 (D-)” 评级，而 HC Wainwright 则给予了 “买入” 评级，目标价为 50 美元。该股票交易价格为 9.69 美元，12 个月的价格区间为 3.76 至 46.80 美元。Aligos 报告的季度每股收益为（1.53 美元），超出预期，市值为 5959 万美元。机构投资者持有该股票的 60.43%。分析师预计共识评级为 “持有”，预计本财年的每股收益为 -10.36</p>

<p>Aligos Therapeutics (NASDAQ:ALGS - Get Free Report)'s stock had its &#34;sell (d-)&#34; rating reaffirmed by equities researchers at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.</p>
<div class="lb-trans"><p>阿里高斯治疗公司（NASDAQ:ALGS - 获取免费报告）的股票在周五发布给客户和投资者的研究报告中被 Weiss Ratings 的股票研究人员重申了 “卖出（d-）” 评级，Weiss Ratings 报告称。</p>
</div><p>Separately, HC Wainwright reissued a &#34;buy&#34; rating and set a $50.00 price target on shares of Aligos Therapeutics in a research report on Friday, September 12th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of &#34;Hold&#34; and an average target price of $50.00.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 9 月 12 日的研究报告中重新发布了 “买入” 评级，并设定了阿里高斯治疗公司股票的目标价为 50.00 美元。一位投资分析师对该股票给予了买入评级，另一位则给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “持有”，平均目标价为 50.00 美元。</p>
</div><p>Get <strong>Aligos Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>阿里高斯治疗公司</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Report on ALGS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ALGS 的最新报告</strong></p>
</div><h2>Aligos Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>阿里高斯治疗公司股票表现</h2>
</div><p>ALGS traded up $0.20 on Friday, hitting $9.69. 26,275 shares of the company were exchanged, compared to its average volume of 150,831. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $46.80. The company has a market cap of $59.59 million, a PE ratio of -0.49 and a beta of 2.77. The stock's fifty day moving average is $10.07 and its 200-day moving average is $7.87.</p>
<div class="lb-trans"><p>周五，ALGS 上涨 0.20 美元，达到 9.69 美元。该公司交易了 26,275 股，较其平均交易量 150,831 股有所减少。阿里高斯治疗公司的 12 个月低点为 3.76 美元，12 个月高点为 46.80 美元。该公司的市值为 5959 万美元，市盈率为-0.49，贝塔值为 2.77。该股票的 50 日移动平均线为 10.07 美元，200 日移动平均线为 7.87 美元。</p>
</div><p>Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.53) earnings per share for the quarter, topping analysts' consensus estimates of ($2.35) by $0.82. The firm had revenue of $0.97 million for the quarter, compared to the consensus estimate of $0.43 million. Aligos Therapeutics had a negative return on equity of 22.41% and a negative net margin of 2,337.24%. As a group, equities research analysts expect that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>阿里高斯治疗公司（NASDAQ:ALGS - 获取免费报告）最近于 8 月 6 日宣布了其季度财报。该公司报告的每股收益为（1.53 美元），超出分析师的共识预期（2.35 美元）0.82 美元。该公司本季度的收入为 97 万美元，而共识预期为 43 万美元。阿里高斯治疗公司的股本回报率为-22.41%，净利润率为-2337.24%。作为一个整体，股票研究分析师预计阿里高斯治疗公司在当前财政年度将发布-10.36 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Aligos Therapeutics</h2>
<div class="lb-trans"><h2>对阿里高斯治疗公司的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in ALGS. Golden State Wealth Management LLC grew its position in Aligos Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company's stock worth $44,000 after buying an additional 2,674 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in Aligos Therapeutics by 43.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 465,000 shares of the company's stock worth $3,836,000 after buying an additional 140,000 shares in the last quarter. Heights Capital Management Inc. acquired a new stake in Aligos Therapeutics during the first quarter worth approximately $1,992,000. Readystate Asset Management LP acquired a new stake in Aligos Therapeutics during the first quarter worth approximately $375,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Aligos Therapeutics during the first quarter worth approximately $3,399,000. Institutional investors and hedge funds own 60.43% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对 ALGS 的持仓进行了调整。Golden State Wealth Management LLC 在第一季度将其在阿里高斯治疗公司的持仓增加了 100.0%。Golden State Wealth Management LLC 现在拥有该公司 5,348 股股票，价值 44,000 美元，此前在上个季度又购买了 2,674 股。Adage Capital Partners GP L.L.C.在第一季度将其在阿里高斯治疗公司的持仓增加了 43.1%。Adage Capital Partners GP L.L.C.现在拥有该公司 465,000 股股票，价值 3,836,000 美元，此前在上个季度又购买了 140,000 股。Heights Capital Management Inc.在第一季度收购了阿里高斯治疗公司的新股份，价值约 1,992,000 美元。Readystate Asset Management LP 在第一季度收购了阿里高斯治疗公司的新股份，价值约 375,000 美元。最后，Alyeska Investment Group L.P.在第一季度收购了阿里高斯治疗公司的新股份，价值约 3,399,000 美元。机构投资者和对冲基金持有该公司 60.43% 的股票。</p>
</div><h2>Aligos Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>阿里高斯治疗公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).</p>
<div class="lb-trans"><p>阿里高斯治疗公司是一家临床阶段的生物制药公司，专注于开发新型治疗药物，以满足病毒和肝病领域未满足的医疗需求。其药物候选者 ALG-055009 是一种小分子 THR-ß激动剂，目前正在进行非酒精性脂肪性肝炎（NASH）的 2a 期临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Aligos Therapeutics</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside</li>
<li>What is a Death Cross in Stocks?</li>
<li>3 Regional Bank Stocks That Crushed Q3 Earnings</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过阿里高斯治疗公司</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>罗技在财报前瞄准突破——花旗看到 30% 的上涨空间</li>
<li>股票中的死亡交叉是什么？</li>
<li>3 只区域银行股票在第三季度财报中表现出色</li>
<li>ETF 支付股息吗？你需要知道的事项</li>
<li>Freeport-McMoRan 尽管印尼停产仍发布强劲财报</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aligos Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在阿里高斯治疗公司吗？</h2>
</div><p>Before you consider Aligos Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑阿里高斯治疗公司之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aligos Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而阿里高斯治疗公司并不在名单上。</p>
</div><p>While Aligos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿里高斯治疗公司目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Aligos Therapeutics（纳斯达克股票代码：ALGS）被 Weiss Ratings 评为卖出（D-）评级